Abstract Number: 0862 • ACR Convergence 2022
Impact of the COVID-19 Pandemic on the Management of Juvenile Idiopathic Arthritis: An Analysis of National United States Administrative Claims Data
Background/Purpose: Limited information exists on COVID-19 pandemic-related changes in the management of rheumatic diseases in adults or children, besides what patients and families have reported.…Abstract Number: 0925 • ACR Convergence 2022
Impact of Initiating Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs on Pain Medication Use in Patients with Rheumatoid Arthritis
Background/Purpose: Chronic pain associated with rheumatoid arthritis (RA) leads to impaired patient function and quality of life. Prior studies suggest initiation of disease-modifying antirheumatic drugs…Abstract Number: 1112 • ACR Convergence 2022
Biosimilar-to-Biosimilar Switching in Routine Care – Results on >1,600 Patients with Inflammatory Arthritis in the DANBIO Registry
Background/Purpose: In routine care, biosimilar-to-biosimilar infliximab switching may occur to save costs (=non-medical switching). Previous studies have investigated the efficacy and safety of switches from…Abstract Number: 1199 • ACR Convergence 2022
Validation of New Medication User Definitions in Single-Specialty EHR Data
Background/Purpose: New user designs are standard in many pharmacoepidemiology studies, but a first prescription appearance in electronic health record (EHR) data may not always represent…Abstract Number: 1213 • ACR Convergence 2022
Trends of Opioid Prescriptions and Impact of the COVID-19 Pandemic Among Patients with Musculoskeletal Diseases Between 2006-2021
Background/Purpose: Opioid prescribing has contributed to a North American epidemic with increasing trends in several European countries. Rheumatic and musculoskeletal diseases (RMDs) are one of…Abstract Number: 1374 • ACR Convergence 2022
Real-World Effectiveness and Steroid Sparing Effect of Belimumab in Pediatric Lupus: A Single Center Retrospective Study
Background/Purpose: Belimumab is the only targeted therapy approved for pediatric systemic lupus erythematosus (pSLE), although use remains limited in children. While clinical trials and studies…Abstract Number: 1429 • ACR Convergence 2022
Acute Cardiovascular Events Risk in Rheumatoid Arthritis Patients Treated with Tofacitinib or TNF Inhibitors, a Nationwide Cohort Study: RELATION Study
Background/Purpose: Patients with IMID, and notably patients with rheumatoid arthritis (RA), are at increased risk of major adverse cardiovascular event (MACE) compared with the general…Abstract Number: 1546 • ACR Convergence 2022
Treatment of Polymyalgia Rheumatica by Rheumatology Providers: Results from the ACR Rheumatology Informatics System for Effectiveness Registry
Background/Purpose: Polymyalgia rheumatica (PMR) is one of the most common systemic rheumatic diseases in older adults. Glucocorticoids (GC) remain the main treatment, and although recommendations…Abstract Number: 0060 • ACR Convergence 2022
Lower Healthcare Costs for Commercially Insured Patients with Rheumatoid Arthritis in Remission
Background/Purpose: Rheumatoid arthritis (RA) affects about 1-2% of adults with annual US costs at $19 billion. Most studies evaluating cost of care have not had…Abstract Number: 1547 • ACR Convergence 2022
Effectiveness of Interleukin-6 Receptor Inhibitors for Polymyalgia Rheumatica
Background/Purpose: Interleukin-6 receptor (IL-6R) inhibition has been shown to be effective in giant cell arteritis but data are limited in polymyalgia rheumatica (PMR). We conducted…Abstract Number: 0074 • ACR Convergence 2022
Real-World Treatment Patterns, Healthcare Resource Utilization (HCRU) and Costs in Patients with Systemic Lupus Erythematosus (SLE) in the US
Background/Purpose: SLE treatment is complex, with a wide variety of medications commonly prescribed. Limited evidence exists in the literature with respect to treatment patterns, HCRU…Abstract Number: 1643 • ACR Convergence 2022
Use of Oral Analgesics and Risk of Comorbidities in Osteoarthritis: Findings from Primary Care Settings in the UK
Background/Purpose: People with osteoarthritis (OA) often have multiple other conditions (comorbidities).Role of different oral analgesics on the development of comorbidities in people with OA have…Abstract Number: 0245 • ACR Convergence 2022
Influence of Forced Vital Capacity Impairment on Treatment Selection and Outcomes in RA-ILD Patients Initiating a Biologic or Targeted-Synthetic DMARD
Background/Purpose: Patients with RA-associated interstitial lung disease (RA-ILD) suffer from substantial morbidity and premature mortality. The optimal use of biologic/tsDMARDs in this population is poorly…Abstract Number: 1648 • ACR Convergence 2022
Risk of Vascular Events Under the Treatments with Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: An Analysis Using Japanese Health Insurance Database
Background/Purpose: Janus kinase inhibitors (JAKIs) have shown positive therapeutic impacts on treatments for rheumatoid arthritis (RA), whereas, concerns have been raised about the risk of…Abstract Number: 0290 • ACR Convergence 2022
Evaluation of Treatment Discontinuation Due to Adverse Events, and the Effect of Cardiovascular Risk Factors or Type of JAK-inhibitors: An International Collaboration of Registries of Rheumatoid Arthritis Patients (the
Background/Purpose: The "ORAL Surveillance" study1 suggests an increased risk of serious adverse events (AEs) with tofacitinib, a JAK-inhibitor (JAKi), compared to TNF-inhibitors (TNFi). Currently, there…
- 1
- 2
- 3
- 4
- Next Page »